⌕
MoonLake Immunotherapeutics · MLTX · Nasdaq
Tenet 51 · Mixed
Compare
$11.73−6.16%At closeTenet 51 · Mixed
$11.73−0.77 (−6.16%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

MoonLake Immunotherapeutics (MLTX) Stock

MoonLake Immunotherapeutics (MLTX) closed at $11.73 on Nov 16, 2026; its Tenet Score is 51 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

35 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$11.73
Nov 16, 2026
Market cap
$1.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
9.46 – 23.29
low → high · as of close, Nov 13, 2026
Tenet Score
51/100
Mixed · 313 Healthcare peers

Industry: Financial Services

MoonLake Immunotherapeutics scores 51/100. Mixed. Strongest on financial health and value, quality is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 51 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=313
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
71
Quality
7
Health
73
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityFHealthBGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.8×
price to book value
P/S
—
no P/S on file
ROE
−81%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
9.13
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase I…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 11 US ETFs · top wrappers by weightSee all ETFs holding MLTX →

Similar-sized companies in Financial Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is MoonLake Immunotherapeutics in?

MoonLake Immunotherapeutics is in the Healthcare sector and the Financial Services industry.

What is MoonLake Immunotherapeutics' Tenet Score?

MoonLake Immunotherapeutics' Tenet Score is 51 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.